| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802862201018 | 286220101 | MIZANTRONE C/S.SOL.IN 20MG/ML BT x 1 VIAL x 2 ML | 12.35 | 12.96 | 17.86 |
| 05/2018 | 2802862201025 | 286220102 | MIZANTRONE C/S.SOL.IN 20MG/ML BT x 1 VIAL x 5 ML | 36.82 | 38.62 | 53.22 |
| 05/2018 | 2802862201032 | 286220103 | MIZANTRONE C/S.SOL.IN 20MG/ML BT x 1 VIAL x 15 ML | 110.45 | 115.86 | 142.46 |
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer.
Irinotecan inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex. The formation of this ternary complex interferes with the moving replication fork, which induces replication arrest and lethal double-stranded breaks in DNA. As a result, DNA damage is not efficiently repaired and apoptosis (programmed cell death) occurs.
Gastrointestinal complications, such as nausea, vomiting, abdominal cramping, diarrhea, and infection.
100%
6-12 hours
The cumulative biliary and urinary excretion of irinotecan and its metabolites (SN-38 and SN-38 glucuronide) over a period of 48 hours following administration of irinotecan in two patients ranged from approximately 25% (100 mg/m2) to 50% (300 mg/m2).